Evaluation of nanoparticle albumin-bound paclitaxel loaded macrophages for glioblastoma treatment based on a microfluidic chip

被引:2
作者
Xie, Zuorun [1 ]
Ye, Junyi [1 ]
Gao, Xinghua [2 ]
Chen, Hang [3 ]
Chen, Maosong [1 ]
Lian, Jiangfang [3 ]
Ma, Jingyun [3 ]
Wang, Hongcai [1 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Dept Neurosurg, Ningbo, Zhejiang, Peoples R China
[2] Shanghai Univ, Mat Genome Inst, Shanghai, Peoples R China
[3] Ningbo Univ, Affiliated Lihuili Hosp, Ningbo Inst Innovat Combined Med & Engn, Ningbo, Zhejiang, Peoples R China
关键词
microfluidic chip; glioblastoma; macrophage-based carrier; drug delivery; nanoparticle albumin-bound paclitaxel; DELIVERY; GLIOMA;
D O I
10.3389/fbioe.2024.1361682
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Glioblastoma (GBM) is a primary brain malignancy with a dismal prognosis and remains incurable at present. In this study, macrophages (M phi) were developed to carry nanoparticle albumin-bound paclitaxel (nab-PTX) to form nab-PTX/M phi. The aim of this study is to use a GBM-on-a-chip to evaluate the anti-GBM effects of nab-PTX/M phi.Methods: In this study, we constructed nab-PTX/M phi by incubating live M phi with nab-PTX. We developed a microfluidic chip to co-culture GBM cells and human umbilical vein endothelial cells, mimicking the simplified blood-brain barrier and GBM. Using a syringe pump, we perform sustainable perfusion of nutrient media. To evaluate the anti-GBM effects nab-PTX/M phi, we treated the GBM-on-a-chip model with nab-PTX/M phi and investigated GBM cell proliferation, migration, and spheroid formation.Results: At the chosen concentration, nab-PTX did not significantly affect the viability, chemotaxis and migration of M phi. The uptake of nab-PTX by M phi occurred within 1 h of incubation and almost reached saturation at 6 h. Additionally, nab-PTX/M phi exhibited the M1 phenotype, which inhibits tumor progression. Following phagocytosis, M phi were able to release nab-PTX, and the release of nab-PTX by M phi had nearly reached its limit at 48 h. Compared with control group and blank M phi group, individual nab-PTX group and nab-PTX/M phi group could inhibit tumor proliferation, invasion and spheroid formation. Meanwhile, the anti-GBM effect of nab-PTX/M phi was more significant than nab-PTX.Discussion: Our findings demonstrate that nab-PTX/M phi has a significant anti-GBM effect compared to individual nab-PTX or M phi administration, suggesting M phi as potential drug delivery vectors for GBM therapy. Furthermore, the developed GBM-on-a-chip model provides a potential ex vivo platform for innovative cell-based therapies and tailored therapeutic strategies for GBM.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Exceptional Response to Nanoparticle Albumin-Bound Paclitaxel and Gemcitabine in a Patient with a Refractory Adenocarcinoma of the Ampulla of Vater
    Kapp, Markus
    Kosmala, Aleksander
    Kircher, Stefan
    Luber, Verena
    Kunzmann, Volker
    CASE REPORTS IN ONCOLOGY, 2016, 9 (01): : 15 - 24
  • [22] Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer
    Shi, Wenjie
    Wan, Xinyu
    Wang, Ye
    He, Jinzhi
    Huang, Xiaofeng
    Xu, Yinggang
    Zhang, Weiwei
    Chen, Rui
    Wang, Lexin
    Zheng, Ran
    Ma, Lingjun
    Li, Xuan
    Xu, Lu
    Zha, Xiaoming
    Wang, Jue
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2023, 49
  • [23] Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel
    Ruttala, Hima Bindu
    Ramasamy, Thiruganesh
    Shin, Beom Soo
    Choi, Han-Gon
    Yong, Chul Soon
    Kim, Jong Oh
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 519 (1-2) : 11 - 21
  • [24] Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer
    Yoshida, Hironori
    Kim, Young Hak
    Ozasa, Hiroaki
    Nagai, Hiroki
    Sakamori, Yuichi
    Nakaoku, Takashi
    Yagi, Yoshitaka
    Tsuji, Takahiro
    Nomizo, Takashi
    Mishima, Michiaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (01) : 213 - 215
  • [25] Nanoparticle Albumin-Bound Paclitaxel and Solvent-Based Paclitaxel as Chemotherapy Options for Patients With Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
    Gangannapalle, Mahesh
    Shahnoor, Husna
    Sattar, Lubna
    Nagi, Talwinder K.
    Al-Tekreeti, Marwah
    Khan, Muhammad Waqas
    Haseeb, Madiha D.
    Khan, Areeba
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [26] Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer
    Yang, Miaomiao
    Qu, Huajun
    Liu, Aina
    Liu, Jiannan
    Sun, Ping
    Li, Hua
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (07) : 1561 - 1566
  • [27] Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer
    Mei, Yu
    Shi, Min
    Zhu, Zhenglun
    Yuan, Hong
    Yan, Chao
    Li, Chen
    Feng, Tienan
    Yan, Min
    Zhang, Jun
    Zhu, Zhenggang
    FUTURE ONCOLOGY, 2021, 18 (02) : 139 - 148
  • [28] Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer
    Kinoshita, Ryo
    Ishima, Yu
    Chuang, Victor T. G.
    Nakamura, Hideaki
    Fang, Jun
    Watanabe, Hiroshi
    Shimizu, Taro
    Okuhira, Keiichiro
    Ishida, Tatsuhiro
    Maeda, Hiroshi
    Otagiri, Masaki
    Maruyama, Toru
    BIOMATERIALS, 2017, 140 : 162 - 169
  • [29] Nanoparticle Albumin-Bound Paclitaxel- and/or Gemcitabine-Induced Scleroderma Accompanied by Acanthosis Nigricans-Like Skin Changes
    Motegi, Sei-ichiro
    Ishikawa, Mai
    Sekiguchi, Akiko
    Ishikawa, Osamu
    CASE REPORTS IN DERMATOLOGY, 2019, 11 (03): : 273 - 277
  • [30] Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer
    Takashima, Tsutomu
    Kawajiri, Hidemi
    Nishimori, Takeo
    Tei, Seika
    Nishimura, Shigehiko
    Yamagata, Shigehito
    Tokunaga, Shinya
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2018, 38 (01) : 379 - 383